2013


To access this material please log in or register

Register Authorize
2013/№3

Registry of patients admitted with the acute decompensated heart failure (ADHF) syndrome: evaluation of clinical picture and therapeutic tactics.

Berezhnaya O. O., Slepneva E. M., Bylova N. A., Arutyunov A. G.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: treatment, acute heart failure, register

DOI: 10.18087/rhfj.2013.3.1786

Background. Chronic HF is one of the most adverse, progressing CVDs. Optimizing the therapy for decompensated circulation is a promising direction in development of current cardiology because such therapy would influence both mortality rate in a population and incidence of complications responsible for the high frequency of hospitalization. Aim. Studying the incidence of complications and concurrent conditions as well as the HF etiology; evaluating the relevance of therapy administered to patients with HF. Materials and methods. 60 patients with acute decompensated HF (ADHF) were selected for the study. ADHF was documented by the presence of at least two of the following signs: dyspnea, rales, peripheral edema, increased jugular pulse, X-ray signs of congestion in pulmonary circulation. Degree of circulatory insufficiency according to the Strazhesko and Vasilenko classification, HF etiology, and presence of complications and concurrent diseases were analyzed. Inpatient therapy was evaluated. Results. The main cause of CHF was shown to be IHD (75 % of cases), including isolated IHD (31.67 %), combination of IHD and AH (33.33 %), and combination of IHD and heart defect (10 %). AH as an independent cause was observed in 20 % of patients. Heart defect was the least frequent cause of HF. The complication incidence was as follows: hydrothorax (48.33 %), pneumonia (46.67 %), and ascites (36.67 %). Atrial fibrillation was found in 63.33 % of patients; DM – in 33.33 %, anemia – in 28.33 %, hypercholesterolemia – in 30.36 %, and increased creatinine level – in 41.3 %. Patients received the following therapies: ACE inhibitors (80 %), β-blockers (78.33), loop diuretics (83.33 %), calcium channel blockers (26.67 %), digoxin (30 %), nitrate (58.33 %), aspirin (81.67 %), and anticoagulants (48.33 %).
  1. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Е. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. – М.: «Гэотар-Медиа», 2006. – 432 с.
  2. Арутюнов Г. П. Бета – блокаторы и сердечная недостаточность. Журнал Сердечная Недостаточность. 2002;3 (1):27–28.
  3. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  4. Чазова И. Е. Двойная блокада ренин-ангиотензиновой системы: новые возможности в лечении сердечно-сосудистых заболеваний. Consilium Medicum. 2007;5:10–12.
  5. Федеральное руководство по использованию лекарственных средств (формулярная система). Под ред А. Г Чучалина., А. И. Вялкова, Ю. Б. Белоусова и др. Вып. V. Перераб. и доп. – М.: ЭХО, 2004.
  6. Мареев В. Ю. Аспирин при хронической сердечной недостаточности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная недостаточность. 2003;4 (19):153–157.
Berezhnaya O. O., Slepneva E. M., Bylova N. A. et al. Registry of patients admitted with the acute decompensated heart failure (ADHF) syndrome: evaluation of clinical picture and therapeutic tactics. Russian Heart Failure Journal. 2013;14 (3):124-126

To access this material please log in or register

Register Authorize
Ru En